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Abstract
Introduction—Targeted cancer therapeutics have demon-
strated more limited clinical efﬁcacy than anticipated, due
to both intrinsic and acquired drug resistance. Underlying
mechanisms have been largely attributed to genetic changes,
but a substantial proportion of resistance observations
remain unexplained by genomic properties. Emerging evi-
dence shows that receptor tyrosine kinase (RTK) reprogram-
ming is a major alternative process causing targeted drug
resistance, separate from genetic alterations. Hence, the
contributions of mechanisms leading to this process need to
be more rigorously assessed.
Methods—To parse contributions of multiple mechanisms to
RTK reprogramming, we have developed a quantitative
multi-receptor and multi-mechanistic experimental frame-
work and kinetic model.
Results—We ﬁnd that RTK reprogramming mechanisms are
disparate among RTKs and nodes of intervention in the
MAPK pathway. Mek inhibition induces increased Axl and
Her2 levels in triple negative breast cancer (TNBC) cells
while Met and EGFR levels remain unchanged, with Axl and
Her2 sharing re-wiring through increased synthesis and
differing secondary contributing mechanisms. While three
Mek inhibitors exhibited mechanistic similarity, three Erk
inhibitors elicited effects different from the Mek inhibitors
and from each other, with MAPK pathway target-speciﬁc
effects correlating with Erk subcellular localization. Further-
more, we ﬁnd that Mek inhibitor-induced RTK reprogram-
ming occurs through both BET bromodomain dependent
and independent mechanisms, motivating combination treat-
ment with BET and Axl inhibition to overcome RTK
reprogramming.
Conclusions—Our ﬁndings suggest that RTK reprogramming
occurs through multiple mechanisms in a MAPK pathway
target-speciﬁc manner, highlighting the need for comprehen-
sive resistance mechanism proﬁling strategies during phar-
macological development.
Keywords—Triple negative breast cancer, EGFR, Her2, Met,
Axl, Mek inhibition, Erk inhibition, BET inhibition.
ABBREVIATIONS
RTK Receptor tyrosine kinase
BET Bromodomain and extra-terminal domain
TNBC Triple negative breast cancer
MAPK Mitogen-activated protein kinase
TKI Tyrosine kinase inhibitor
PCA Principal component analysis
ELISA Enzyme linked immunosorbent assay
MEKi Mek inhibitor
BETi BET inhibitor
AXLi Axl inhibitor
LLOQ Lower limit of quantitation
INTRODUCTION
Detailed genetic understanding of molecular cancer
drivers has enabled the development of targeted cancer
therapeutics. Well-characterized cancer targets such as
mutant EGFR in non-small cell lung cancer (NSCLC)
and the BCR-Abl fusion gene in chronic myelogenous
leukemia (CML) led to initial breakthroughs,12,31,37
and success via this approach has continued to expand
as more than 150 targeted therapeutics have been ap-
proved to date by the FDA to treat various cancer
subtypes.48 Unfortunately, sustained therapeutic efﬁ-
cacy has been limited by the emergence of drug resis-
tance. Enabled by broadening availability of advanced
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genome sequencing technologies, genetic mechanisms
of drug resistance have been widely identiﬁed—com-
monly mutation or ampliﬁcation in the target itself or
alternate proteins.14,35,36,41 However, emerging evi-
dence is showing that non-genetic mechanisms also
contribute signiﬁcantly to drug resistance, such that a
substantial proportion of resistance cannot be readily
attributed to genetic lesions. For instance, target and
alternative receptor tyrosine kinases (RTKs) can ex-
hibit enhanced activities via increased expression even
in the absence of gene ampliﬁcation,4,10,35,46,49 includ-
ing by means of modulated ligand binding and/or
receptor oligomerization.25,50,52 Due to the many
RTKs that may contribute to resistance, monitoring
coordinated changes in RTK networks, termed ‘‘RTK
reprogramming’’, has become important for evaluating
cancer drug resistance.10,13,45
While identiﬁcation of mutation or ampliﬁcation of
the target protein can lead to improved second and
third line inhibitors that have advantageous properties,
such as alternate binding motifs, covalent binding, or
the combination of antibodies and small molecule
inhibitors,26,40 elucidation of additional activated
proteins, whether alternative RTKs or downstream
signaling molecules, can guide combination treatment
with inhibitors against a second target. When gene
expression networks are broadly altered, it may be
useful to employ epigenetic inhibitors, such as bro-
modomain and extra-terminal domain (BET) in-
hibitors, to limit the dynamic response of numerous
potential targets simultaneously.9
A highly relevant clinical application representing a
major unmet treatment need is triple negative breast
cancer (TNBC), which is an aggressive disease
accounting for approximately 15% of invasive breast
cancers and is deﬁned as progesterone receptor (PR)
negative, estrogen receptor (ER) negative, and Her2
negative.38 Although lacking traditional markers
identiﬁed in breast cancer, the EGFR inhibitor erloti-
nib has been shown to have subtype speciﬁcity for
basal/TNBC.21 Furthermore, 37% of patient samples
classiﬁed as TNBC overexpress EGFR.38 However, in
a phase II study of Cetuximab for EGFR inhibition in
combination with carboplatin for treatment of TNBC,
fewer than 20% of patients responded to treatment
even though they had EGFR activation prior to
treatment. Analysis of pre- and post-treatment biopsy
samples found that the EGFR pathway was upregu-
lated in 81% of pre-treatment samples and eight of
thirteen patients retained high EGFR pathway
expression in the presence of EGFR inhibition, indi-
cating pathway maintenance downstream of EGFR.5
As the MAPK pathway is one of the major signal
transduction pathways downstream of EGFR that
promotes growth and survival, it has been studied for
its role in TNBC. In fact, approximately 80% of
TNBCs have ampliﬁcation in EGFR, KRAS, or
BRAF proteins, providing a rationale for targeting the
MAPK pathway.27 Further, TNBC cell lines are pref-
erentially sensitive to Mek inhibition supporting
MAPK inhibition in TNBC.23
Despite this compelling rationale, pre-clinical and
clinical evidence indicates that TNBC cells undergo
RTK reprogramming, limiting response to Mek inhi-
bition.13,34 While RTK reprogramming has been de-
scribed as a transcriptionally regulated event,13,45 work
from Miller et al. demonstrated abrogation of RTK
ectodomain shedding as an alternative mechanism.34
With multiple competing, or more likely complemen-
tary, hypotheses found in different studies, a need is
clear for a more integrative perspective on how mul-
tiple mechanisms may concomitantly contribute to
drug resistance even through a particular phenomenon
such as dynamic alterations in RTK levels.
Our work here accordingly aims to develop an
integrative framework based on quantitative experi-
mentation and a computational model that quantiﬁes
contributions of non-genetic mechanisms to many al-
tered RTK levels in parallel. By leveraging non-speciﬁc
cell labeling and antibody speciﬁc measurements we
have developed a methodology that is amenable to
systems level characterization and provides robust
estimates for parameters that are historically cumber-
some to measure directly. We apply this framework in
the context of drug resistance to MAPK inhibition in
TNBC to clarify the absolute contributions of com-
peting processes. In doing so, we show that Axl and
Her2 levels increase following Mek inhibition not only
through increased synthesis but also through sec-
ondary mechanisms, including decreased protein
degradation and endocytosis. Additionally, receptor
degradation and endocytosis decreased broadly with
only context-speciﬁc quantitative eﬀects on RTK levels
and decreased proteolytic shedding does not quanti-
tatively contribute to altered cellular RTK levels.
Furthermore, we identify diﬀerences in the RTK
reprogramming response to Mek inhibitors vs. Erk
inhibitors. Taken together, we have identiﬁed integra-
tive, RTK speciﬁc, and MAPK inhibitor-speciﬁc RTK
reprogramming responses in TNBC.
RESULTS
Integrative Model Quantiﬁes Mechanistic Cellular
Processes and Basal Cell State
We used the model structure depicted in Fig. 1 to
describe the mechanistic processes of interest govern-
ing protein levels and subcellular localization. Brieﬂy,
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RTKs are either on the cell surface, intracellular (en-
dosomal/lysosomal/nuclear), or free ectodomains are
circulating in the extracellular environment (super-
natant). Zeroth order protein synthesis adds protein to
the cell surface, while ﬁrst order rate constants govern
transport between the compartments by proteolytic
shedding, endocytosis, recycling, and degradation.
To inform the model, both end point and time-
course experiments were performed to capture pro-
cesses manifesting over both fast and slow time scales
and provide additional unique model information. As
summarized in Fig. 2, end point measurements are
made by treating cells for 24 h. Lysate and supernatant
samples are quantiﬁed with a multi-plexed bead-based
ELISA and recombinant protein standard. Time-
course measurements are pulse-chase experiments,
whereby cell surface proteins are non-speciﬁcally la-
beled with a cleavable, cell impermeable biotin. After
varying incubation times from 5 to 90 min to facilitate
labeled protein trafﬁcking, cells are either lysed in
whole or after the cell surface biotin label is stripped,
yielding an internal pool of labeled protein. Samples
are then measured by total protein pull-down with
primary antibodies in a multi-plexed bead-based ELI-
SA and labeled protein detection with a streptavidin
conjugate, permitting relatively straightforward multi-
plexing. This technique combines biotinylation non-
speciﬁcity of binding to essentially all accessible sur-
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FIGURE 1. Model schematic. Axl (blue), Met (orange), EGFR
(green), and Her2 (purple) receptors exist in one of three
compartments: Cell surface (rs), intracellular (combined
endosomal, lysosomal, nuclear) (ri), or freely circulating in
the extracellular medium (rf). Psyn represents net protein
synthesis, the sum of transcriptional and translational
regulation, kdeg represents protein degradation from the
internal compartment, kshed represents proteolytic shedding
of cell surface extracellular domains, and kend and krec
represent endocytosis and recycling to and from the internal
protein pool (i.e., endosomes) respectively.
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FIGURE 2. Experimental methodology for measuring varying RTK levels and kinetics. (left) End point experiment workflow
whereby after 24-h treatment lysate and supernatant samples are collected and measured by bead-based ELISA with a recombinant
protein standard. (right) Time-course experiment workflow whereby cell surface proteins are non-specifically labeled with biotin,
labeled proteins are trafficked over varying time points, and surface biotin is either cleaved or un-cleaved. Samples are measured
with an adapted bead-based ELISA. Colors represent two proteins measured simultaneously and independently.
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face proteins with antibody speciﬁcity to selectively
quantify those proteins of particular interest. Fur-
thermore, the direct labeling and measurement of the
protein of interest allows us to characterize the basal
cell state in addition to perturbation effects (as op-
posed to traditional methods dependent on a labelled
ligand or antibody binding effects), further increasing
the applicability of this methodology.
To characterize the basal cell state of MDAMB231
TNBC cells, we collected end point and time-course
measurements for Axl, Met, EGFR, and Her2 in
control treated cells (Figs. 3a and 3b). Axl, Met, and
EGFR are highly expressed at levels on the order of
105–106 molecules/cell, consistent with values charac-
terized previously for EGFR in cancer cell lines.44 We
also found high supernatant levels of Axl and Met,
ranging from ~ 1 to 6% of lysate levels shed per hour
respectively, highlighting the rapid turnover of protein
through proteolytic shedding. Furthermore, we ob-
serve different RTK kinetics, with biotinylated Met
levels turning over the most rapidly and internal Axl
levels accumulating to the highest relative level.
We utilized Bayesian statistics to calculate the pos-
terior probability for model parameters, identifying
parameter distributions accounting for experimental
variability which provides a more comprehensive
characterization than single point estimates. Further-
more, we leveraged prior distributions to enable esti-
mation of biologically relevant parameter regimes
without over-constraining parameters based on litera-
ture values from diﬀerent proteins, cell lines, or envi-
ronmental contexts. Parameter estimation was ﬁrst
performed via a deterministic direct search algorithm
with 100 semi-random start sites identiﬁed by latin
hypercube sampling (see ‘‘Materials and Methods’’).
While we observe start site dependent local optima for
optimized negative log(posterior) values across RTKs,
we also observe a convergence to what we presume to
be the global minimum posterior value (Fig. 3c). As
such, deterministic optimization yields our presumed
global optimum parameter set. To address parameter
variability and generate distributions as opposed to
single point estimates, we used an adaptive metropolis
algorithm to generate the full parameter posterior
distributions describing the experimental data
(Fig. 3d).
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FIGURE 3. Quantitative experiments and parameter estimation define MDAMB231 cell basal state. (a) End point sample
quantification for total lysate (left) and supernatant (right) samples for control treated MDAMB231 cells. mean 6 standard
deviation, n = 12. (b) Time-course measurement of total biotin labeled RTK (left) and internal biotin labeled RTK (right) samples for
control treated MDAMB231 cells. mean 6 standard deviation, n = 18. (c) Optimized posterior value from deterministic
patternsearch algorithm for 100 start sites determined by latin hypercube sampling and ordered by increasing -log(posterior)
values. (d) Parameter posterior distributions from adaptive metropolis algorithm. Data are summed from 4 independent chains,
100,000 iterations each, minus 20,000 step burn-in period. Psyn has units of molecules cell
21 min21 and kdeg, kend, krec, and kshed
have units of min21. Blue—Axl, orange—Met, green—EGFR, purple—Her2.
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Generally, parameter values across RTKs for
endocytosis, recycling, degradation and synthesis were
consistent with published literature values for
EGFR15,17,18,22,39,51 and Axl endocytosis and recycling
rates were similar to those estimated from a model of
ligand-receptor interaction and trafﬁcking.33 In addi-
tion to estimated values consistent with literature re-
ports, we ﬁnd relatively narrow distributions for
parameter estimates with the methodology developed
here. Compared to traditional trafﬁcking measurement
methods that depend on radioactive or ﬂuorescently
labeled ligands and treatment with broad-spectrum
inhibitors which are often toxic to the cells, we were
able to achieve constrained parameter estimates with
experiments that are readily accessible, extendable, and
avoid using inhibitors that may introduce off-target
effects.
Of note, EGFR degradation and synthesis have
limited comparability to literature values as a conse-
quence of low identiﬁability and strong parameter
covariation which was not observed with other recep-
tors and treatments. Furthermore, we observe a
roughly uniform distribution for Her2 kshed although
there was no Her2 measured in the supernatant. This is
a result of assuming the supernatant measurement can
be any value less than the lower limit of quantitation
(LLOQ) such that the Her2 kshed distributions herein
represent biologically plausible shedding rates that
would yield un-detectable supernatant levels consistent
with our experimental measure. While EGFR kinetics,
and Her2 kinetics to a lesser extent, have been well-
documented in the literature, we have gained insights
here into the basal cellular behavior of the less studied
Axl and Met receptors.
To validate the ability of our experimental and
computational framework to quantitate cellular
mechanistic processes, we used two perturbations with
known cellular eﬀects. First, cells were stimulated with
EGF which is known to internalize EGFR and Her2
and down-regulate lysate levels.22,39,44 Indeed, EGFR
and Her2 lysate levels were decreased after 24 h
whereas Axl and Met levels remained unchanged
(Supplemental Fig. 1a). Additionally, receptor inter-
nalization was increased for EGFR and Her2 and the
endocytosis (kend) parameter distribution was
increased for cells stimulated with EGF (Supplemental
Figs. 1b, 1c). Second, cells were treated with batimas-
tat, a broad-spectrum metalloprotease inhibitor which
has been used to decrease proteolytic shedding of Axl
and Met.34 Axl and Met lysate levels were increased
after 24 h with batimastat treatment with a concomi-
tant decrease in the supernatant levels, consistent with
model estimations of decreased kshed (Supplemental
Fig. 2). For both cases and all other treatments used
herein, we ﬁnd good agreement between experimental
data and simulated data generated from randomly
sampling 10% of parameter sets (i.e., sampling from
adaptive metropolis steps, maintaining parameter
covariate relationships) for both end point data
(Figs. 4a and 5a, Supplemental Figs. 1a, 2a, 6a, 7a)
and time-course data (Supplemental Figs. 1b, 2b, 3, 4).
This provides conﬁdence that the parameter posterior
distributions on which we draw biological conclusions
not only ﬁt the data well but also reﬂect the underlying
sources of variability in the data. Together, these two
examples highlight the ability of the methodology to
capture and quantify known RTK speciﬁc perturba-
tions.
Mek Inhibitors Alter Axl and Her2 Levels Through
Distinct Integrative Mechanisms
Three Mek inhibitors, selumetinib, binimetinib, and
PD0325901, were tested for their induction of RTK
reprogramming. To allow for compound dependent
downstream eﬀects (i.e., viability, RTK reprogram-
ming), we used concentrations that were 100 times
greater than the reported in vitro IC50 values for target
inhibition. We ﬁnd that the three compounds have
different IC50 values in MDAMB231 cells, although
the selected concentration values result in similar in-
hibitory effects (Supplemental Fig. 5).
After 24-h treatment, MDAMB231 and SUM159
cells had increased Axl and Her2 lysate levels and
decreased Axl and Met supernatant accumulation rel-
ative to lysate levels (represented as percent shed)
(Fig. 4a, Supplemental Fig. 6a). Parameter distribu-
tions underlying the treatment induced changes are
shown in Fig. 4b and Supplemental Fig. 6b. Looking
across RTKs, we observe multiple trends in compar-
ison to control treatment. First, we see a decrease in
endocytosis (kend) across all inhibitors and RTKs.
Second, Axl and Met degradation (kdeg) and shedding
(kshed) are decreased across Mek inhibitors and to a
greater extent in MDAMB231 cells. Third, Axl and
Her2 synthesis (Psyn) are increased across inhibitors.
Although the mechanisms described here (endocytosis,
degradation, etc.) represent fundamental cellular pro-
cesses, the identiﬁcation of RTK speciﬁc effects indi-
cates underlying molecular details, such as mediator
proteins and their abundance, activity, or co-localiza-
tion, are likely driving the mechanism context depen-
dency.
While changes in broad parameter distributions are
informative as to how cellular processes are changing,
we wished to quantitate how these changes translated
to changes in RTK abundance. To quantitate the eﬀect
of treatment-induced parameter distribution changes,
lysate levels were predicted using the mean parameter
values for control treatment and singly substituting
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mean parameter values for each treatment. The model
therefore allows one to predict the quantitative con-
tribution of individual parameter mean changes rela-
tive to the entire treatment induced changes for total
protein levels. For Her2, we ﬁnd that protein synthesis
is the dominant driver of increased lysate levels, al-
though decreased endocytosis has secondary contri-
butions as well (Fig. 4b, Supplemental Fig. 6b). Axl,
on the other hand, is equally governed by the increased
protein synthesis and decreased degradation rates,
with smaller contributions from decreased endocytosis.
Her2 mRNA levels have been reported to increase with
Mek inhibition;13 however, Axl levels have not been
reported to have signiﬁcantly altered mRNA levels13,34
(unpublished in-house data). Two hypotheses are
consistent with both pieces of data, the ﬁrst that
mRNA to protein levels do not always correlate well30
such that small, statistically insigniﬁcant mRNA
changes could yield signiﬁcant protein changes, and
the second that protein synthesis control occurs post-
transcriptionally.
Although these model predictions are based on
mean parameter values, we assessed the contributions
of parameter variability to model predictions using
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FIGURE 4. Mek inhibitors increase Axl and Her2 lysate levels and alter multiple parameter estimations. (a) (left panel) End point
lysate measurements and (right panel) end point percent shed (rf/rt) levels normalized to the mean control treated value for
MDAMB231 cells treated for 24 h with three Mek inhibitors. Points indicate experimental data (n = 12) and shaded bars represent
the range of simulated data from resampling 10% of parameter sets. Asterisk indicates p < 0.01 and ÆÆ indicates p < 0.05 with a two-
sample t test with Bonferroni multiple hypothesis correction. (b) Parameter posterior distributions (summed for 4 independent
chains, 100,000 iterations each, 20,000 step burn-in time) for control and Mek inhibitor treated cells and predicted protein level fold
change relative to control treatment (red dots indicate observed treatment fold change). Psyn has units of molecules cell
21 min21
and kdeg, kend, krec, and kshed have units of min
21. Black—control, blue—selumetinib, orange—binimetinib, green—PD0325901.
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10,000 randomly sampled control and treated param-
eter sets (Supplemental Fig. 8). We ﬁnd the distribu-
tion of predicted changes for the conclusions drawn
above to have little to no overlap with an unchanged
value of 1, providing support for the predictive
capacity in the presence of parameter variability.
Surprisingly, we saw that the decreases in prote-
olytic shedding had only quantitatively minor pre-
dicted eﬀects on lysate levels in the cell line models
tested here, although it has previously been shown to
serve as a biomarker for poor patient progression free
survival in melanoma patients treated with Mek and
Braf inhibitors.34 Further study in systems with higher
levels of shed protein will be needed to gain a better
understanding of if and when proteolytic shedding is a
major contributor to drug resistance. Importantly, our
result here does not eliminate a potential role of pro-
teolytic shedding in other models and our analysis
framework highlights the importance of quantitative
modeling for distinguishing between correlative and
causative changes. Additionally, our methodology
identiﬁes a yet un-studied contributor to Mek inhibitor
induced RTK reprogramming, decreased protein
degradation and endocytosis.
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FIGURE 5. Erk inhibitors have compound dependent parameter changes that vary from Mek inhibition. (a) (left panel) End point
lysate measurements and (right panel) end point percent shed (rf/rt) levels normalized to the mean control treated value for
MDAMB231 cells treated for 24 h with three Erk inhibitors. Points indicate experimental data (n = 12) and shaded bars represent the
range of simulated data from resampling 10% of parameter sets. Asterisk indicates p < 0.01 and ÆÆ indicates p < 0.05 with a two-
sample t test with Bonferroni multiple hypothesis correction. (b) Parameter posterior distributions (summed for 4 independent
chains, 100,000 iterations each, 20,000 step burn-in time) for control and Mek inhibitor treated cells and predicted protein level fold
change relative to control treatment (red dots indicate observed treatment fold change). Psyn has units of molecules cell
21 min21
and kdeg, kend, krec, and kshed have units of min
21. Black—control, blue—ulixertinib, orange—DEL-22379, green—GDC-0994.
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Erk Inhibitors Have Compound Dependent Eﬀects
that Vary from Mek Inhibitors
To compare the RTK reprogramming eﬀect fol-
lowing inhibition of the MAPK pathway at diﬀerent
points, we similarly tested three Erk inhibitors, ulix-
ertinib, DEL-22379, and GDC-0994. When compared
to Mek inhibitors, we see that only one of the Erk
inhibitors, ulixertinib, increased Axl and Her2 lysate
levels in MDAMB231 cells and had no eﬀect in
SUM159 cells (Fig. 5a, Supplemental Fig. 7a). Addi-
tionally, ulixertinib increases Met and EGFR levels in
MDAMB231 cells, showing differences from Mek in-
hibitors. These increases are primarily driven by
increased synthesis of all RTKs with an absence of
decreased protein degradation and endocytosis
(Fig. 5b). Interestingly, ulixertinib and GDC-0994 are
both Erk TKIs whereas DEL-22379 is an Erk dimer
inhibitor. Not only do we see different responses
within TKIs, but these responses, as well as Mek in-
hibitors, are further different from DEL-22379, indi-
cating that variations in Erk dimerization is not
driving the observed differences seen here (Fig. 5,
Supplemental Fig. 7).
MAPK Pathway Has Target-Speciﬁc RTK
Reprogramming
We utilized principal component analysis (PCA) to
identify the greatest variation across cell lines and in-
hibitors (scores) and the variables (loadings) con-
tributing to these changes. PCA was performed with
two diﬀerent variable deﬁnitions: (1) mean parameter
values (Figs. 6a and 6b) and (2) predicted protein
change (Figs. 6c and 6d). In both cases, there is a clear
separation between Mek and Erk treated samples, with
Erk inhibitor treated samples more similar to control
treated. Axl and Her2 synthesis (Psyn), Axl, Her2 and
Met endocytosis (kend), and Axl, Met, and Her2
degradation (kdeg) are among the loadings of largest
magnitude and with directionality consistent with
Mek-Erk score separation in both PCA analyses,
indicating they are major drivers of the MAPK target
speciﬁc RTK reprogramming response observed.
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FIGURE 6. Principal component analysis identifies separation of Mek and Erk inhibitors and cell type specific responses. (a) and
(b) Scores and Loadings plots respectively for PCA analysis where mean parameter values were used as variables. (c) and (d)
Scores and Loadings plots respectively for PCA analysis where predicted protein fold change values were used as variables. In
Scores plots, circles indicate control treated samples, squares indicate Mek inhibitor treated samples, and diamonds indicate Erk
inhibitor treated samples. Filled symbols indicate MDAMB231 cells while open symbols indicate SUM159 cells. In Loadings plots,
variables are color coded by RTK (blue—Axl, orange—Met, green—EGFR, purple—Her2) and mechanistic processes are labeled
accordingly.
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We further observe cell type speciﬁc eﬀects as a shift
from Control/Erk to Mek treatment along principal
component 1 for MDAMB231 cells and along princi-
pal component 2 for SUM159 cells. Whereas Mek in-
hibitors alone decrease endocytosis (kend) in
MDAMB231 cells, both Mek and Erk inhibitors de-
crease endocytosis in SUM159 cells. Alternatively, Met
protein synthesis (Psyn) is decreased with Mek inhibi-
tion and unaffected with Erk inhibition in SUM159
cells and unaffected with both Mek and Erk inhibition
in MDAMB231 cells. Cell speciﬁc responses are not
surprising, especially considering their varying genetic
background (MDAMB231- Kras mutant,23 PIK3CA
wild type42 SUM159- Hras mutant, PIK3CA mutant),3
although further study is needed to address contribu-
tions of these genetic factors to the varying RTK
reprogramming phenotypes observed.
Mek and Erk inhibitors had diﬀerent eﬀects on Erk
phosphorylation where Mek inhibitors decreased Erk
phosphorylation (T202/Y204) and Erk inhibitors did
not (Fig. 7, Supplemental Fig. 9). Two hypotheses for
phosphorylation site effects are around Erk dimeriza-
tion and subcellular localization. As we have already
observed protein levels and parameter distributions
with an Erk dimer inhibitor, DEL-22379, that vary
from those of Mek and Erk TKIs, it is unlikely that
differences in Erk dimer formation in a phospho-site
dependent manner describe the observed Mek and Erk
inhibitor differences. However, Erk nuclear
localization is decreased speciﬁcally with Mek inhibi-
tion (Fig. 7, Supplemental Fig. 9), consistent with the
role of Erk phosphorylation on nuclear transport.7
Mek and BET Inhibition Have Diﬀering Eﬀects,
Motivating Combination Treatment and Sensitizing
Cells to Axl Inhibition
In the case of cellular RTK reprogramming whereby
no single alternate target exists for combination
treatment, the use of epigenetic regulators to prevent
the transcriptional response has been postulated and
tested in certain models.8,45 In TNBC cell lines, Mek
induced RTK reprogramming was reported to act
through de-stabilization of Myc, inducing transcrip-
tion of proteins that are normally repressed.13 JQ1, a
BET bromodomain inhibitor, was developed to inhibit
the recognition of acetylated lysine residues by BET
family proteins and not only has shown some speci-
ﬁcity for Myc driven genes11 but other genetic targets
as well.2,43 Additionally, JQ1 was found to be effective
at inhibiting viability in TNBC cell lines in vitro and
in vivo43 as was previously seen for Mek inhibitors.23
Although both Mek and BET inhibition are methods
of perturbing Myc genetic regulation it is unclear
whether their mechanism of action is redundant and
thus is of interest to compare the RTK rewiring
response for both treatments alone and in combina-
tion. Furthermore, Mek inhibitor increased Her2 levels
were primarily driven by protein synthesis while Axl
levels were only driven in part. Through combination
treatment with Mek and BET inhibition (with the ca-
veat that JQ1 has target speciﬁcity that may not in-
clude Her2 and Axl), we can test the model predictions
for the quantitative synthesis role for Her2 and Axl
and expect that combination treatment would return
Her2 levels to baseline whereas Axl levels would re-
main elevated.
Whereas both Mek inhibition (selumetinib) and
BET inhibition (JQ1) had anti-proliferative and anti-
migratory eﬀects alone, combination treatment further
inhibited both processes (Fig. 8a). Interestingly, Her2
lysate levels were increased with Mek but not BET
inhibition yet the combination of the two reduced Her2
levels back to baseline (Fig. 8b). This ﬁnding indicates
that the Mek inhibitor-induced Her2 transcription
becomes BET dependent whereas basal transcription is
not. On the other hand, Mek inhibition and BET
inhibition both increased Axl levels, resulting in sus-
tained high Axl protein and phosphorylation levels
(data not shown) with combination treatment. Com-
bined, this further sensitized cells to inhibition with
R428, an Axl inhibitor, whereby R428 had no anti-
proliferative effect in combination with either Mek or
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BET inhibitor alone but does in the combined back-
ground of Mek + BET inhibition. Together, these re-
sults not only support the use of Mek and BET
inhibitors in combination due to their non-overlapping
and context-dependent effects on RTK reprogram-
ming, but further support combination inhibition of
Axl in this context.
DISCUSSION
An integrative, multi-receptor model developed here
expands our knowledge of targeted cancer therapy-
induced RTK reprogramming by providing mecha-
nistic insights into the underlying processes responsible
for changes in RTK levels. Previous work has de-
scribed the RTK reprogramming phenotype as a
transcriptionally regulated event,13,45 putting the
spotlight on BET inhibitors as viable treatment op-
tions to prevent resistance onset. Our work addition-
ally identiﬁes the presence of non-synthesis mediated
changes in protein levels, the therapeutic implications
for which have yet to be explored in greater detail.
We describe divergent RTK reprogramming phe-
notypes between Mek and Erk inhibitors, indicating
that Mek and Erk inhibitors should not be considered
interchangeable. Assuming that both Mek and Erk
inhibitors decrease Erk kinase activity, diﬀerences
could be driven by Erk phosphorylation dependent
cellular localization, protein binding, or alternate Mek
substrates. While we have not assessed diﬀerences in
Erk binding to target proteins with Mek or Erk in-
hibitors, we have observed decreased Erk nuclear
localization following Mek but not Erk inhibition. In
addition to the traditional role of Erk substrate phos-
phorylation, Erk has been found itself to be associated
with chromatin,24,32 potentially acting as a transcrip-
tion factor to link subcellular localization and protein
synthesis variations with Mek and Erk inhibitors.
Further studies characterizing Erk DNA binding with
Mek and Erk inhibitors may help shed light on this
hypothesis. Interestingly, Erk TKIs had a less pro-
nounced effect on RTK reprogramming in the recep-
tors studied here than Mek inhibition, which may be
desired when considering a therapeutic option, yet cell
proliferation was largely insensitive to Erk inhibition.
Characterizing the RTK reprogramming in cells that
are sensitive to Erk inhibition may help to understand
if adaptation and efﬁcacy are intrinsically connected
within the MAPK pathway or if Erk inhibition main-
tains minimal effects on RTK reprogramming. An
expansion of our knowledge of the molecular targets
susceptible to RTK reprogramming may help charac-
terize ideal targets within a pathway.
In addition to protein synthesis, the processes of
endocytosis, degradation, and proteolytic shedding are
largely decreased with Mek inhibition relative to con-
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FIGURE 8. Mek and BET inhibitor combinations improve response and sensitize cells to Axl inhibition. (a) Phenotypic drug
response for MEKi (selumetinib, 1.5 lM), BETi (JQ1, 0.2 lM), and AXLi (R428, 1 lM) in MDAMB231 cells. Proliferation (black) and
Migration (grey) responses, represented by either % confluence of the entire well or of the wound respectively, were measured for
varying single and combination treatments. Proliferation measurement was after 100 h and migration measurement was after 24 h.
Mean 6 standard deviation with n = 8. (b) Lysate levels in molecules/cell for RTKs when treated with control, MEKi, BETi, or
MEKi 1 BETi in MDAMB231 cells. Points indicate experimental data (n = 12) and crosses indicate mean values. Asterisk indicates
p < 0.01 and ÆÆ indicates p < 0.05 determined by pairwise t tests with Bonferroni correction.
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trol treatment and Erk inhibition. While these pro-
cesses constitute post-synthesis mechanisms with re-
spect to controlling RTK levels, it is plausible that the
proteins governing these processes themselves are
transcriptionally altered with MAPK inhibition.
Interestingly, Mek has been shown to bind and phos-
phorylate heat shock factor 1 (HSF1), facilitating nu-
clear localization and transcription of heat shock
proteins which are involved in a wide array of cellular
processes including vesicular transport and protein
degradation.20,47 As an effect upstream of Erk activity,
HSF1 is an intriguing candidate protein for broadly
affecting cellular processes such as endocytosis and
degradation with Mek inhibition alone. As altered
trafﬁcking and degradation were a surprising outcome
of the model predictions that spanned across RTKs, it
will be important to continue to study these processes
linked to drug resistance. As regulators of cellular
homeostasis, characterizing the molecular players
responsible for the adaptive response as well as iden-
tifying the extent that proteins not looked at in this
study are affected by these processes will continue to
expand our understanding of systems level changes
with targeted therapeutics.
While BET inhibitors are being clinically evaluated
as monotherapies, limited pre-clinical evidence shows
beneﬁt for their use in combination to overcome RTK
reprogramming resistance.45 However, molecular
understanding for rational combinations with BET
inhibitors is currently limited. Although JQ1 was
originally described to preferentially inhibit Myc
transcriptional networks in multiple myeloma,11 new
studies identify additional pathway effects for BET
inhibition in alternate model systems.2,43 Furthermore,
BET inhibitors not only inhibit transcription of BET
activated genes, but they also induce transcription of
BET repressed genes. As such, the molecular details of
treatment with BET inhibitors or Mek inhibitors alone
are not fully characterized and we have limited ability
to predict combination treatments to attenuate RTK
reprogramming and the subsequent resistance. To this
point, both Mek and BET inhibitors have been de-
scribed to affect transcriptional networks by inhibiting
Myc, either by de-stabilization and protein degrada-
tion or reducing transcription and interrupting Myc-
adaptor-chromatin interactions respectively. Yet the
combination of the two has a larger anti-proliferative
and anti-migratory response than either alone.
Furthermore, BET inhibition has no eﬀect on Her2
levels when used alone but reduces Her2 levels in
combination treatment with Mek inhibition, indicating
Mek inhibitor induced BET dependency. Axl, how-
ever, is increased by both Mek inhibition and BET
inhibition, retaining high levels with combination
treatment such that cells are further inhibited by the
addition of an Axl inhibitor. Following our hypothesis,
this data indicates a Mek inhibitor induced loss of Erk
transcriptional repression for Her2 and Axl whose
newly active transcription is mediated in a BET
dependent and independent manner respectively. Ta-
ken together, this indicates a lack of redundancy in the
cellular targets and provides rationale for combining
the two treatments, although relief of repressed tran-
scriptional targets remains an issue for drug resistance.
The suitability of these combinations will likely be
context dependent and further study is needed to
identify the governing rules.
Although our focus here is on RTK levels, there is
an underlying assumption that these altered levels are
indicative of increased signaling activity, promoting a
cell survival response to MAPK inhibition. As Mek
inhibition leads to increases in Axl and Her2 phos-
phorylation13,34 and we have found that increased Axl
levels with Mek and BET inhibition correspond to a
context dependent anti-proliferative effect of Axl
inhibition, we believe our characterization of RTK
levels is a suitable surrogate measurement. We have
also limited our study to four RTKs and two cell lines.
While these comparisons have enabled interesting in-
sights regarding RTK speciﬁc responses, integrative
mechanisms, and Mek vs. Erk inhibitor variable
responses, studies of a larger scale of both proteins and
cell lines will further the understanding and implica-
tions of these trends for improved selection of combi-
nation treatments. Fortunately, the combination of
non-speciﬁcity of cell surface biotinylation and anti-
body mediated speciﬁcity for experimental measure-
ments coupled to a generalized model structure
grouping complex protein dependent processes (i.e.,
ligand induced receptor dimerization/heterodimeriza-
tion) into representative processes was purposeful to
facilitate the adaptation to further proteins of interest
without requiring detailed a priori understanding. A
potential limitation of the lumped parameters, how-
ever, is that they may represent multiple underlying
rates. For instance, EGFR and Her2, known
heterodimerization partners, have been shown to
internalize at different rates when homo- or
heterodimerized,22 the combination of which will be
captured with our model. The model and methodology
could be extended to include a cross-linking protocol
with different capture and detection antibodies for the
heterodimerization partners to explicitly quantify the
endocytosis rate to de-convolve the lumped parameter
to provide better granularity if it were desired.
In summary, we have shown that using a model to
extract mechanistic meaning from quantitative experi-
ments allows us to understand the cellular processes
altered by MAPK inhibition. We have further utilized
model predictions to quantitate the eﬀects of individual
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cellular process changes with inhibition, identifying
multiple processes contributing to the RTK repro-
gramming phenotype. In doing so, we identiﬁed RTK
dependent, integrative responses that varywith diﬀerent
MAPK target inhibitors. Taken together, the results
propose a more complex picture of RTK reprogram-
ming whereby no single mechanistic change, such as
protein synthesis, alters RTK levels but there is a dy-
namic, integrative response. Increased understanding
and accounting of this complexity will undoubtedly
improve rational combination treatment selection to
overcome resistance to targeted cancer therapies.
MATERIALS AND METHODS
Cell Culture, Reagents, and Compounds
MDAMB231 cells were purchased from ATCC and
grown in DMEM (Gibco) media supplemented with
10% FBS, 1% Pen/strep, and 1% Glutamax Supple-
ment (Thermo Fisher) and maintained at 37 C in 5%
CO2. SUM159 cells were purchased from Asterand
Bioscience and grown according to manufacturer’s
suggestion. Recombinant human EGF was used at
10 nM. Batimastat (BB94, Tocris Bioscience) was used
at 10 lM. Selumetinib (AZD6244, Selleck Chem) was
used at 1.5 lM. Binimetinib (Mek162, ARRY-162,
Selleck Chem) was used at 1.2 lM. PD0325901 (Sel-
leck Chem) was used at 33 nM. Ulixertinib (BVD-523,
VRT752271, Selleck Chem) was used at 30 nM. DEL-
22379 (Selleck Chem) was used at 5 lM. GDC-0994
(Selleck Chem) was used at 30 nM. JQ1 (Tocris Bio-
science) was used at 0.2 lM. R428 (BGB324, Selleck
Chem) was used at 1 lM. DMSO at matched con-
centrations was used as all controls.
Cell Lysis and Supernatant Collection
Prior to lysis, 200 lL of the cellular supernatant was
transferred to a 96 well v-bottom plate. Cells were
lysed with 50 lL NP40 lysis buffer (20 mM Tris–HCl,
150 mM NaCl, 2 mM EDTA, 1% NP40, 10% Glyc-
erol, pH 7.4). Plates were shaken for 15 min at
~ 8000 rpm at 4 C. Lysates were transferred to a 96
well v-bottom plate and lysates and supernatant sam-
ples were clariﬁed by centrifugation for 15 min at
~ 23009g. Samples were stored at  20 C prior to
use.
Luminex Reagents and Antibody-Bead Coupling
Capture antibodies for Axl, Met, EGFR, and Her2
were purchased from R&D Systems (MAB154,
MAB3581, AF231, and MAB1129 respectively).
Biotinylated detection antibodies for Axl, Met, EGFR
and Her2 were purchased from R&D Systems
(BAF154, BAF358, BAF231, and BAF1129 respec-
tively). Streptavidin Phycoerythrin (SAPE) was pur-
chased from Biorad (cat. no. 171304501). Assay
diluent and washing buﬀer used in all steps was 0.1%
BSA + 0.1% Tween20 in 19 PBS.
100 lL MagPix beads (Luminex Corp.) were cen-
trifuged at 10,0009g for 2 min and the supernatant
was discarded. EDC (N-(3-dimethylaminopropyl)-N¢-
ethylcarbodiimide, Sigma) and S-NHS (N-hydroxy-
sulfosuccinimide, Pierce) were dissolved in diH20 to
50 mg/mL. Beads were incubated with 80 lL activa-
tion buffer (100 mM NaH2PO4 pH 6.3), 10 lL EDC,
and 10 lL S-NHS for 20 min dark at room tempera-
ture shaking at ~ 900 rpm. The mixture was cen-
trifuged at 10,0009g for 2 min and the supernatant
was discarded. Antibodies were diluted to 0.1 mg/mL
in 100 lL coupling buffer (50 mM HEPES, pH 7.4)
and incubated with the bead suspension, overnight
shaking, at 4 C. The following day beads were washed
39 and resuspended in 1 mL 1% BSA + 1% Tween20
in 1x PBS and stored at 4 C.
Luminex Bead-Based ELISA Procedure
Capture antibodies were each diluted 759 into assay
diluent (0.1% BSA + 0.1% Tween20 in 19 PBS) and
25 lL was added to each well in a 384 well Optiplate
(Perkin Elmer). The plate was brieﬂy centrifuged at
2009g for 1 min and washed 39 with 80 lL wash
buffer (0.1% BSA + 0.1% Tween20 in 19 PBS).
Samples were added to each well according to the
following dilutions. End point measurement lysates
were diluted at both 259 and 109 in assay diluent to a
ﬁnal volume of 25 lL per well with data selected for
further use based on location in the log-linear range of
the standard curve. Supernatants were supplemented
with 5% solution volume 0.1% BSA in 19 PBS to a
ﬁnal volume of 50 lL. Standard curves were prepared
at matched volumes and diluent concentrations as all
samples. Samples were incubated with the capture
antibody beads overnight shaking at ~ 8000 rpm at
4 C. The following day the plate was centrifuged at
2009g for 1 min and washed 39 with 80 lL wash
buffer. Detection antibody was diluted 10009 into
assay diluent and 15 lL was added to each well. The
plate was centrifuged at 2009g for 1 min, incubated at
room temperature for 1 h, and washed 39 with 80 lL
wash buffer. SAPE was diluted 1009 into assay diluent
and 15 lL was added to each well. The plate was
centrifuged at 2009g for 1 min, incubated shaking at
room temperature for 15 min, and washed 39 with
80 lL wash buffer. After the ﬁnal wash 60 lL assay
diluent was added to each well. Samples were read on a
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Flexmap 3D machine (Luminex Corp) according to
manufacturer’s protocol.
Time-Course Experiments
Cells were seeded at 50,000 cells/well and SUM159
cells were seeded at 18,750 cells/well in 48 well plates
overnight. The following day cells were washed 19
with PBS and 125 lL of 0.5 mg/mL Sulfo-NHS-SS-
Biotin (Pierce) was added to each well and incubated
for 1 h at 4 C with gentle agitation. Cells were washed
19 with PBS followed by addition of treatment and
incubated at 37 C for 5, 20, 45, 75, or 90 min. Fol-
lowing incubation, cells were washed 19 with Reduc-
ing Buffer (50 mM Tris, 150 mM NaCl, pH 8.6) and
cells were either stripped with the addition of 20 mM
sodium 2-mercaptoethanesulfonate (MESNA, Sigma)
or non-stripped with Reducing buffer and incubated
for 1 h at 4 C with gentle agitation. The stripping
reaction was quenched by addition of 40 mM
Iodoacetamide (IAA, Sigma) for 10 min at 4 C with
gentle agitation. Cells were washed 19 with PBS and
lysed. Lysates were measured for total biotin signal
(surface un-stripped with MESNA) and internal biotin
signal (surface stripped with MESNA) with an adapted
Luminex protocol, eliminating the detection antibody
step. Independent experimental replicates were nor-
malized to the mean of the measured total biotin signal
at the ﬁrst time point.
End Point Experiments
MDAMB231 cells were seeded at 50,000 cells/well
and SUM159 cells were seeded at 18,750 cells/well in
48 well plates overnight. The following day controls
and treatments were added to 6 replicate wells for 24 h.
Following treatment, supernatant and lysate were
collected. Axl, Met, EGFR, and Her2 levels were
simultaneously quantiﬁed in samples by bead-based
ELISA (Luminex Corp) with recombinant protein
standards (R&D systems).
Absolute Receptor Quantiﬁcation
End point measurements were converted from the
measured mean ﬂuorescence intensity (MFU) to
absolute quantity (mr) in pg by ﬁve-parameter logistic
regression to a recombinant protein standard. Subse-
quently, measurements were converted to receptor
concentration (r, molecules/cell) through the following
relationship:
r ¼ mr  dil  protcell  navg
cprot MWRTK  vlys ð1Þ
where dil is the fraction of the total lysate and super-
natant measured respectively, cprot is the concentration
of total protein in the lysate as measured by BCA as-
say, MWRTK is the molecular weight of the recombi-
nant protein standard, vlys is the volume of lysate
collected, navg is Avogadro’s number, and protcell is the
protein content per cell, estimated here as 300 pg/cell
as reported for HeLa cells.29
For absolute quantiﬁcation, DMSO control treated
samples were collected on three separate days (bio-
logical day replicates), on two separate plates each day
(biological plate replicates), with 3 replicate wells per
plate (technical plate replicates). Lysate and super-
natant samples were collected and measured for
MDAMB231 and SUM159 cells on 3 independent
bead-based ELISA plates, with individually prepared
reagents, including standard curves, on each plate. On
plate standard curves were averaged and on plate
samples were converted based on the mean standard
curve. Absolute RTK quantiﬁcation was calculated as
the median RTK quantitation value (across biological
day, plate and technical replicates) in a given condition
(cell line, lysate vs. supernatant). For subsequent
measurements, the oﬀset was calculated as the fold
change between the DMSO control in-experiment
median value to the absolute quantitation value. This
oﬀset was applied to individual experimental points
across all treatments, eﬀectively shifting the experi-
mental data to account for variations in the standard
curve.
Surface Fraction Assay
Cells were seeded overnight at the above described
densities. The following day media was changed and
cells were incubated at 37 C for 24 h. Subsequently,
cells were washed 19 with PBS and 125 lL of 0.2 mg/
mL cell permeable NHS-SS-Biotin (Pierce) was added
to each well and incubated for 1 h at 4 C with gentle
agitation. Cells were then washed 19 with Reducing
Buffer (50 mM Tris, 150 mM NaCl, pH 8.6) and cells
were either stripped with the addition of 20 mM so-
dium 2-mercaptoethanesulfonate (MESNA, Sigma) or
non-stripped with Reducing buffer and incubated for
1 h at 4 C with gentle agitation. The stripping reac-
tion was quenched by addition of 40 mM Iodoac-
etamide (IAA, Sigma) for 10 min at 4 C with gentle
agitation. Cells were washed 19 with PBS and lysed.
Lysates were measured for total biotin signal (not
stripped with MESNA) and internal biotin signal
(surface stripped with MESNA) with an adapted Lu-
minex protocol, eliminating the detection antibody
step.
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Cell Viability Assay
MDAMB231 cells were seeded at 2500 cells/well
and SUM159 cells were seeded at 2000 cells/well
overnight in 96 well plates. The following day treat-
ments were added and cells were incubated for 72 h at
37 C and 5% CO2. Viability measurements were made
using CellTiter-Glo Luminescent Cell Viability Assay
(Promega) per manufacturer’s suggestions.
Proliferation Assays
MDAMB231 cells were plated at 2500 cells/well in
96 well plates overnight. The following day treatments
were added and cells were incubated for 100 h at 37 C
and 5% CO2. Plates were measured for percent con-
ﬂuence in the well using the IncuCyte Zoom System
and Software (Essen Bioscience).
Migration Assays
MDAMB231 cells were plated at 25,000 cells/well in
96 well plates overnight. The following day, a wound
was made with a 96-well WoundMaker (Essen Bio-
science) and wells were washed twice with 19 PBS.
Treatments were added to wells and plates were mea-
sured for percent conﬂuence in the wound using the
IncuCyte ZOOM System and Software (Essen Bio-
science) at 24-h post treatment.
Cell Fixation, Staining, and Immunoﬂuorescence
Imaging
Cells were seeded onto 35 mm glass-bottom dishes
with MDAMB231 cells at 100,000 cells/dish and
SUM159 cells at 50,000 cells/dish overnight. On the
second day treatments were spiked into the media for
4 h. Media was aspirated then cells were covered with
4% formaldehyde diluted in PBS at 37 C for ﬁxation.
After 15 min at room temperature plates were rinsed in
PBS. Cells were then covered with ice-cold 100% me-
thanol for permeabilization. After 15 min at  20 C
the methanol was aspirated and the plates rinsed in
PBS. Blocking was performed in Odyssey Blocking
Buﬀer (PBS) for 60 min and then the buﬀer aspirated.
The primary antibodies used were diluted (1:400 p-
p44/42 MAPK (Erk1/2) [Thr202/Tyr204] and p44/42
MAPK (Erk1/2) [L34F12]) in Odyssey Blocking Buﬀer
(PBS) and incubated overnight at 4 C. Cells were
again rinsed in PBS. Fluorochrome-conjugated sec-
ondary antibodies used were diluted (1:200 Donkey
anti-Mouse IgG Fluor 594, Donkey anti-Rabbit IgG
Fluor 488) in Odyssey Blocking Buﬀer (PBS). DAPI
was used to stain the nuclei for segmentation purposes
(1:10,000). After 1 h at room temperature in the dark,
cells were aspirated and rinsed in PBS before imaging.
Imaging was performed on a Nikon Ti spinning disk
Confocal Microscope with wide-ﬁeld at 20x.
Immunoﬂuorescence Image Processing and Analysis
To analyze single-cell immunostaining of Erk and
pErk, images were processed and analyzed as follows
using in-house MATLAB scripts (Mathworks, Inc).
Images were exported at the microscope-acquired bit
depth using Nikon Elements software. Cell nuclei were
ﬁrst localized and segmented using point-source
detection1 with a 2D Gaussian standard deviation of 6
pixels from the DAPI images, and segmented objects
smaller than 42 lm2 were empirically categorized as
debris and removed. For cell body segmentation, the
Erk immunostained images were used. The Erk-stained
images were ﬁrst retrospectively ﬂat-ﬁeld corrected to
remove uneven illumination by ﬁrst generating a ﬂat-
ﬁeld image. This image was generated by averaging all
Erk-stained images on a pixel-by-pixel basis and
applying a 100 9 100 pixel median ﬁlter to the aver-
aged image. Each Erk image was then divided on a
pixel-by-pixel basis by the ﬂat-ﬁeld image. Cell bodies
were then segmented using the ﬂat-ﬁeld corrected Erk-
stained images by combining the overlap in fore-
grounds of intensity-based Otsu thresholding and
Canny edge detection masks, followed by morpho-
logical closing of objects using a disk structural ele-
ment of 2 pixels, and removal of all mask spur pixels.
Putative cell body objects not overlapping with at least
one pixel of the segmented nuclei mask were consid-
ered debris and removed. Touching cells were split
from each other using a propagation algorithm28 part
of the CellProﬁler tool.6 Nuclei centers detected during
the localization stage above were used as seeds to split
nuclei objects using propagation with a regularization
parameter of 5. Segmented and split nuclei were then
used as seeds for the cell body mask, whereby cell
bodies were split using propagation with a regulariza-
tion parameter of 0 to fully utilize intensity variation in
the objects to split touching cells. To analyze
immunostaining signal intensities in the nucleus and
cytoplasm of cells, local segmentation of nuclei was
ﬁrst performed by Otsu-based thresholding of the
DAPI signal within each segmented cell body cropped
image individually. The locally-segmented nuclear
masks were eroded using a disk structural element of 2
pixels, to minimize the chance of including cytoplasm
region pixels in the nuclei masks. The cytoplasm
regions were deﬁned as the cell body masks excluding
the locally-segmented nuclei mask regions for each cell.
For nucleus, cytoplasm, and whole-cell (nu-
cleus + cytoplasm) compartments for each cell, mean
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pixel intensity was computed in the immunostained
images.
Model Structure
The model schematic is shown in Fig. 1 whereby
receptors exist in 1 of 3 compartments: Cell surface
(rs), intracellular (combined endosomal, lysosomal,
nuclear) (ri), or freely circulating in the extracellular
medium (rf). Movement between compartments is
governed by the following processes: newly synthesized
protein inserted to the cell membrane (Psyn), protein
degradation from the internal protein pool (lysosomal
or proteasomal pathways) (kdeg), proteolytic cleavage
of protein ectodomains from the cell surface to freely
circulating the supernatant (kshed), endocytosis from
the cell surface to the internal compartment (kend), and
recycling from the internal pool to the cell surface
(krec). These parameters are semi-mechanistic in that
they lump more detailed processes, such as receptor-
ligand binding and interaction with trafﬁcking or
degradation mediated proteins, to give an overview
rate of the entire process. Based on mass action
kinetics, we describe the system as:
dri
dt ¼ kendrs  krec þ kdeg
 
ri ð2Þ
drs
dt ¼ Psyn þ krecri  kend þ kshedð Þrs ð3Þ
drf
dt ¼ kshedrs ð4Þ
with units of molecules cell1 min1 for Psyn and min
1
for kdeg, kend, krec, and kshed. As the end point experi-
ments measure lysate and supernatant quantities,
Eq. (4) is used to quantitate supernatant measures
while drt/dt = dri/dt + drs/dt is used to quantitate ly-
sate measures. The time-course data is assumed to not
measure protein synthesis as it is a pulse-chase exper-
iment, altering Eq. (3) above to become
drs
dt ¼ krecri  kend þ kshedð Þrs ð5Þ
Measured quantities in the time-course experiment are
ri(t) (total labeled biotin internal to the cell with time)
and rt(t) (total labeled biotin in the whole cell with
time), where drt/dt = dri/dt + drs/dt.
Bayesian Inference for Parameter Estimation
In order to estimate the parameters for the model in
Fig. 1, we simultaneously ﬁt to both steady state and
time-course data to capture the redundancy in
parameters between data types. We undertake an
approach that allows us to generate full parameter
probability distributions, as opposed to a single best ﬁt
parameter set. Additionally, we incorporate expected
values for a given parameter through setting a prior
distribution as opposed to single literature-based val-
ues, allowing the results to reﬂect known quantitation
for RTK mechanisms without constraining the result
to any single RTK or condition. These goals are
achieved using Bayes Theorem,
P HjXð Þ ¼ P XjHð ÞP Hð ÞP Xð Þ ð6Þ
Which states that the posterior probability distribution
(P HjXð Þ) is proportional to the product of the likeli-
hood of the data (P XjHð Þ) and the prior probability
distribution (P Hð Þ) for a given parameter. P Xð Þ is the
probability of the data which we do not calculate as
P HjXð Þ is calculated as a ratio between step i and
i + 1. Operating in log space and assuming that log-
transformed data is normally distributed, we calculate
the data likelihood for any given parameter set as:
log Likelihoodð Þ ¼ LL ¼
X
e
X
t
X
r
 bye;t  ye;t;r
 2
2r2e
 log reð Þ  1
2
log 2pð Þ
ð7Þ
where by is the simulated value, y is the experimental
data, and LL values are summed over experiment type
e (end point vs. time-course, supernatant vs. lysate,
internal vs. total biotin), time points t (when applica-
ble), and replicates r. Sigma (rÞ is the standard devi-
ation of the data for experiment type e, where the
median value from all cell lines, receptors, and treat-
ments is used as a set value for any given experiment
type.
Prior Distribution Selection
The prior distribution for kshed was approximated
directly by the end point experimental data. Assuming
rs is time invariant, integrating Eq. (4) and rearranging
identiﬁes
kshed ¼ rfrtfsDt ð8Þ
where Dt is the duration of the end point experiment
and fs is the protein surface fraction. Surface fraction
was measured using a cell permeable, cleavable biotin
linker (NHS-SS-Biotin). Based on this in-house data
(Supplemental Fig. 10), fs was modeled to have
mean = 0.85 and standard deviation = 0.1 with
boundary conditions at [0, 1]. Similarly, rf and rs have
mean and standard deviation values from 12 replicate
measures. Using 10,000 iterations, random values were
drawn for fs, rf and rs from their associated normal
distributions to calculate a data-based distribution for
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kshed. The distribution calculated for kshed was then
represented as a mean and standard deviation. As rs
was found to change with treatment, we evaluated an
alternative extreme assumption whereby rt linearly
approaches its treatment induced end point measure-
ment and numerically integrated Eq. (4) with a time-
dependent rs. We found kshed estimates indistinguish-
able from those calculated above, indicating rs
dynamics have a negligible effect on kshed estimation.
As the Her2 supernatant measurement was unde-
tected, the value rf was instead represented by a uni-
form distribution from 1 to 89 molecules cell1 h1
and randomly sampled as for the distributions for
measured data. The LLOQ was calculated to be 89
molecules cell1 h1 by ﬁnding the lowest point in the
standard curve greater than 5 times the average
background value and whose back-ﬁt value was within
20% of the real value. From the resulting uniform
distribution for Her2 kshed, minimum and maximum
values were used as the lower and upper bounds of a
uniform distribution used for the prior distribution.
With the exception of Her2 kshed, prior values were
calculated assuming log transformed parameter values
were normally distributed, such that
log Priorð Þ ¼P
p
 ðblplpÞ
2
2r2p
 log rp
  12 log 2pð Þ ð9Þ
where p are different parameters (kdeg, kend, etc.), blp is
the current test parameter value, lp is the prior dis-
tribution mean parameter value, and rp is the prior
distribution standard deviation. kshed values for lp and
rp were as calculated above, whereas the other lp
values were estimated from the literature to be as fol-
lows: 102 for kdeg,
15,18 kend,
17,22,51 krec
17 and 102 for
Psyn.
39 Values were based on low end estimates as
observed for EGFR as it is most commonly reported
for the ligand stimulated case. rp values were set to 10
2
yielding wide priors, reﬂecting our lack of knowledge
of the true parameter value for any given protein or
condition.
Parameter distributions were ﬁrst estimated for the
control treated case, after which the prior distributions
to be used for comparative treatments were updated to
reﬂect the mean of these distributions. The control
estimated parameter distribution standard deviation
was expanded by twofold which we found optimal to
maintain the goodness of ﬁt to new data while mini-
mizing parameter non-normality.
Non-parametric priors included surface fraction
and initial conditions. Surface fraction values with
mean = 0.85, standard deviation = 0.1 and bound-
ary conditions at [0, 1] were used as for kshed calcula-
tion. For end point data, initial supernatant
concentrations, rf,0, were assumed to be zero due to
media washout and initial lysate concentrations, rt,0,
had a prior distribution representing the mean and
standard deviation of the control treated case. Initial
conditions for time-course data had mean values equal
to that of the t = 5 time point with standard deviation
values = 10 to allow for any dynamic changes
between t = 0 and 5 min.
Sequential Deterministic and Stochastic Optimization
Implementation
We used a multi-step parameter estimation work-
ﬂow to optimize global optimization as well as gener-
ate statistically based parameter distributions. First,
we performed global optimization in Matlab (Math-
works) using the built-in patternsearch function using
100 parameter start sites generated using latin hyper-
cube sampling. Upper and lower parameter bounds
were set to [ 6,0] for kdeg, kend, krec, and kshed and [0 5]
for Psyn, reﬂecting expansions on the prior distribu-
tions selected. The parameter set across all optimized
start sites yielding the minimum objective function
value was assumed to be the global optimum. Second,
we performed local optimization for distribution cal-
culation in Matlab (Mathworks) by altering the mh-
sample function to represent an adaptive metropolis
algorithm19 for improved trace walk convergence. The
adaptive metropolis function was run with initial
covariance C0 = 0.01 for t0 ¼ 100, scaling term
sd= 0.2, and e = 10
20. Initial start site was semi-
randomly generated for 4 chains by drawing a random
start site from a normal distribution with mean of the
global minimum parameter value and 5% coefﬁcient of
variation and run for 100,000 iterations. Chain con-
vergence was assessed visually and by Gelman Rubin
convergence criteria 16 assuming random start sites
within a local environment instead of for global opti-
mization. The ﬁrst 20,000 steps were discarded as the
burn-in period.
Predicted Lysate Levels
Control and treatment parameter distributions were
reduced to mean values. Starting with the control
treated parameter vector, each parameter mean for the
treated case is individually substituted into the control
vector and total lysate levels were simulated then
normalized to the control treated lysate level to rep-
resent the treatment single parameter induced fold
change.
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Principal Component Analysis (PCA)
PCA was performed in Matlab (Mathworks) using
the pca function where the rows of the data block
represent the cell lines and inhibitor treatments. Col-
umns of the data block were performed in two differ-
ent ways. First, the columns used were mean parameter
distribution values for all parameters and all RTKs
measured. Second, the columns used were the pre-
dicted lysate level changes for a given parameter and
RTK. Unchanged variables were determined by ran-
domly sampling 10% of parameter values from control
and treated distributions, generating a difference dis-
tribution, and calculating the smaller of the fraction of
samples above or below zero, representing a metric for
distribution overlap. An arbitrary cutoff value was
used such that distributions with more than 25%
overlap with control were set to the control mean
parameter value or set to predicted lysate fold change
of one for the respective variable deﬁnition. Columns
were z-score normalized across treatments for indi-
vidual cell lines and then analyzed together to account
for variations in absolute parameter magnitude across
cell lines.
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